Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428616 · ClinicalTrials.gov registry record · Phase 2
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
A Phase 2 study, sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07428616 is a Phase 2 study that is actively recruiting participants, run by Exelixis. The registered enrollment target is 100 participants.
The verdict
NCT07428616, a Phase 2 study, is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Interventions
- DRUG Zanzalintinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07428616
The ClinicalTrials.gov registry entry for NCT07428616 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT07428616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07428616 about?
NCT07428616 is a clinical study titled "A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma". The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
What is the current status of trial NCT07428616?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-05-21. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT07428616?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT07428616?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.